Health Sciences — Foreign currency translation adjustments
Cognizant Health Sciences — Foreign currency translation adjustments remained flat by 0.0% to $5.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 253.8%, from -$3.25M to $5.00M. Over 4 years (FY 2021 to FY 2025), Health Sciences — Foreign currency translation adjustments shows an upward trend with a 25.7% CAGR.
Analysis
How to read this metric
Positive adjustments indicate a favorable currency tailwind, while negative adjustments signal a headwind that may mask underlying operational performance.
Detailed definition
This metric captures the impact of fluctuations in foreign exchange rates on the financial results of the Health Science...
Peer comparison
Standard across multinational IT services companies that report segment-level performance in a single currency while operating globally.
ctsh_segment_health_sciences_foreign_currency_translation_adjustmentsHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | -$8.00M | -$14.00M | $6.00M | -$13.00M | $20.00M |
| YoY Change | — | -75.0% | +142.9% | -316.7% | +253.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Cognizant's health sciences — foreign currency translation adjustments?
- Cognizant (CTSH) reported health sciences — foreign currency translation adjustments of $5.00M in Q4 2025.
- How has Cognizant's health sciences — foreign currency translation adjustments changed year-over-year?
- Cognizant's health sciences — foreign currency translation adjustments increased by 253.8% year-over-year, from -$3.25M to $5.00M.
- What is the long-term trend for Cognizant's health sciences — foreign currency translation adjustments?
- Over 4 years (2021 to 2025), Cognizant's health sciences — foreign currency translation adjustments has grown at a 25.7% compound annual growth rate (CAGR), from -$8.00M to $20.00M.
- What does health sciences — foreign currency translation adjustments mean?
- The gain or loss in the Health Sciences segment's financial results caused by changes in currency exchange rates.